Tirzepatide (30 mg Vial)
Tirzepatide (30 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
CAT No:
CAS No:
Synonyms/Alias:Tirzepatide
M.F/Formula:
M.W/Mr.:
Purity:Specification by inquiry
- Sequence, purity and scale confirmation
- CoA and technical documentation requests
- API, research and cosmetic peptide options
- Distributor and institution quotation support
Tirzepatide (30 mg Vial) is supplied as a lyophilized vial for laboratory research use. This page covers reconstitution volume, the resulting concentration, U-100 syringe equivalents and storage handling.
Quickstart
Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Notes
Practical considerations for consistency and safety. Use new sterile insulin syringes; dispose in a sharps container [7]. Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation [8]. All doses through 10 mg/week fit in a single 1 mL syringe at this concentration. Inject slowly; wait a few seconds before withdrawing the needle. Document weekly dose, date, and injection site to maintain consistency. Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them [1].
Single peptide protocol reference : Available for related research, development or formulation inquiry workflows.: Available for related research, development or formulation inquiry workflows.
Reconstitution and handling reference : Available for related research, development or formulation inquiry workflows.: Available for related research, development or formulation inquiry workflows.
Research-use documentation inquiry : Available for related research, development or formulation inquiry workflows.: Available for related research, development or formulation inquiry workflows.
Peptide Vials (Tirzepatide, 30 mg each): 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 1 vial
12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 2 vials
16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 4 vials
Insulin Syringes (U‑100, 1 mL): 8 weeks: 8 syringes (1/week)
12 weeks: 12 syringes (1/week)
16 weeks: 16 syringes (1/week)
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution. 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each administration day. Per week: 2 swabs (1 injection day)
8 weeks: 16 swabs → recommend 1 × 100‑count box
12 weeks: 24 swabs → recommend 1 × 100‑count box
16 weeks: 32 swabs → recommend 1 × 100‑count box
Send product, purity, quantity, destination and documentation requirements. Our team will follow up through online consultation or email.
WhatsApp: +852 52102460 +1 4422847013
Address: Huangpu District, Guangzhou, China